Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

Summary

Background A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission. Methods and Findings 6,537 infants aged 6–12 wk and 8,923 children aged 5–17 mo were randomized to receive three doses of RTS,S/AS01 or comparator vaccine. VE against clinical malaria in children during the 18 mo after vaccine dose 3 (per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p<0.01 across all sites). VE during the 20 mo after vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%), respectively (ITT). VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%], ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization. Post-vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and from 117 to 335 EU/ml in infants (per protocol). VE waned over time in both age categories (Schoenfeld residuals p<0.001). The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365 and from −1 to 49, respectively; corresponding ranges among infants were −10 to 1,402 and −13 to 37, respectively (ITT). Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively. Conclusions RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current malaria control in Africa.

Key Points

• 1RTS,S/AS01 demonstrated an overall efficacy of 46% against clinical malaria in children
• 2Vaccine efficacy was higher in children compared to infants
• 3The study included over 15,000 participants across 11 sites in Africa
• 4Safety surveillance reported serious adverse events, including cases of meningitis
• 5Results indicate the RTS,S/AS01 vaccine could significantly aid malaria control efforts in endemic regions.

Related articles

• Evaluating large language models for clinical note processing: local fine-tuning and internal-external validation using electronic health records from South Asia

  This research paper evaluates the effectiveness of large language models for processing clinical notes from electronic health records in South Asia, focusing on local fine-tuning and validation. It discusses the potential application of LLMs in clinical settings, particularly in resource-limited environments.

• Cardiac Cycle & Physiology: Understanding Cardiac Function

  This document provides a detailed overview of cardiac physiology, including the cardiac cycle, blood flow processes, and the cardiac conduction system. It aims to inform readers about the mechanics of the heart and its role in circulation.

• Cardiac Cycle & Physiology

  This document provides a comprehensive overview of cardiac cycle phases, blood flow through the heart, and the electrophysiology of cardiac conduction. It details the processes of deoxygenation and oxygenation of blood and the physiological aspects of cardiac output and common cardiovascular assessment findings.

• The Dual Pillars of Clinical and Community Care

  This document provides an in-depth examination of nutritional assessment and surveillance in clinical and community settings, offering guidelines on measuring malnutrition indicators and the importance of dietary interventions.

• Cather Simpson Lecture Research Brief Inaugural David Breen

  Cather Simpson Lecture Research Brief Inaugural David Breen Lecture | 14 October 2026 | 12 pm to 1 pm | AM103 The "Nespresso" of Diagnostics: Centrifugal Microfluidics for Point-of-Care Diagnostics; “Can we